Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Phase III Trial Begins For GAMMAGARD LIQUID Plus RHuPH20 In Primary Immunodeficiency Patients (Medical News Today) |
 |
 |
|
Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID). |
